|
|
|
Daphne Lainson specializes in securing patent protection for chemical, pharmaceutical and biotechnology related inventions. She is a lawyer, a qualified patent and trade-mark agent, and holds an advanced degree in chemistry. She has been assisting clients with securing patent protection for their innovations for over a decade.
Daphne champions and safeguards the intellectual property rights of her clients, protecting their inventions in new drugs, biologics, medical devices, consumer products, agrochemicals, specialty chemicals, industrial chemical processes, oil, gas and petrochemicals.
She also provides advice to clients on pharmaceutical regulatory law. This includes providing strategic advice during patent prosecution and following patent grant for both pharmaceuticals and biologics. She is called upon to advise innovative pharmaceutical and biopharmaceutical companies in matters relating to the Patented Medicines (Notice of Compliance) Regulations and the Patented Medicine Prices Review Board.
Daphne is sought after to provide advice and guidance to many of the top global innovators.
She is actively involved in the American Intellectual Property Law Association (AIPLA). She is the current chair of the AIPLA Mentoring Committee, past chair of the AIPLA Women in Intellectual Property Law Committee, and a member of the AIPLA Intellectual Property Practice in Japan Committee.
She plays a leading role in client relations management within the firms, particularly in key industrial markets, such as the U.S., Japan and Germany.
Rankings and recognition
- Named by LEXPERT as one of Canada's 2012 Rising Stars — Leading Lawyers Under 40
- Named Ottawa Businesswoman of the Year 2011 in the professional category by the Women's Business Network of Ottawa
|
|
|
Memberships
- Fellow, Intellectual Property Institute of Canada
- Member, American Intellectual Property Law Association; Chair of the Mentoring Committee; past Chair of the Women in Intellectual Property Law Committee
- Member, Chemical Institute of Canada, Canadian Society for Chemistry
- Member, The Women's Business Network of Ottawa
- Member, Canadian Bar Association; member of the Patent Committee
Speaking engagements
- "Subsequent Entry Biologics (SEBs) – Canada," AIPLA Mid-Winter meeting , Las Vegas, NV, January 2012; AIPLA webinar, March 2012
- "Making contributions visible," 3rd Annual Women in Law conference, Calgary, AB, October 2009
- "Partnerships: Policy and Research at the Crossroads: University-Industry Research Collaborations," 58th Canadian Chemical Engineering Conference, Ottawa, October 2008
- "Patenting Therapeutic/Diagnostic Delivery Devices—Maximizing Marketing Potential," BioNorth Conference on Driving Global Innovation and Commercialization Through Partnerships, Ottawa, November 2007
Publications
- "Patentable subject matter" (co-authors: Steven B. Garland and Kevin K. Graham), Canadian Patent Law Benchbook 2012
- "Evergreen IP," Intellectual Property Magazine, November 2012
- "More effective protection for pharmaceuticals" (co-author: Steven B. Garland), Intellectual Property Magazine, July/August 2012
- "Marketing Innovative Drugs in Canada," Corporate Livewire's Expert Guide: Intellectual Property, December 2011, pp. 72-74
- "The utility of it all," Intellectual Property Magazine, November 2011
- "Double Trouble: Canadian Courts Continue to Clarify the Law on Double Patenting," Intellectual Property Magazine, May 2010
- "Canada Paves the Way for Subsequent Entry Biologics (SEBs)" (co-author: David E. Schwartz), Pharmaceutical Law Insight, May 2009
- "A New Line in the Sand: Supreme Court of Canada considers 'Obvious to Try' and clarifies novelty and selection inventions," (co-author: Steven B. Garland), Patent World, April 2009
- "What Brands Need to Know: Top 10 Tips for Successfully Protecting Exclusivity in the New Regulatory Framework" (co-authors: Gunars A. Gaikis and L. Catherine Eckenswiller), paper presented at the Canadian Institute seminar Pharmaceutical & Biotech Regulatory Compliance, March 2007
- "Biotechnology: Recent Developments of Importance" (co-author: David E. Schwartz), The 2007 LEXPERT/ALM Guide to the Leading 500 Lawyers in Canada, January 2007, pp. 164-167
- "Patenting life forms" (co-author: Elizabeth A. Hayes), Canadian Chemical News/L’Actualité chimique canadienne, October 2006, Vol. 58, No. 9, pp. 18-19
- "Unique IP Issues in Canada's Pharmaceutical and Biotechnology Industry" (co-authors: Gunars A. Gaikis and David E. Schwartz), The 2006 LEXPERT Guide to the Top 100 Industry Specialists in Canada, October 2006, pp. 125-129
- "Chemical and Biomedical Patenting in Canada: From Procurement to Enforcement," presented by John Morrissey at the Royal Chemical Society symposium Creating Business Through World Patent Enforcement, March 2006
- "New Drug Discovery — Beyond the Bench-Top," Canadian Chemical News, April 2006
- "Biopharma Innovators Stand to Benefit from Proposed Data Protection Regulations" (co-authors: May M. Lee and Joy D. Morrow), Bio-Science Law Review, Vol. 7, Issue 2, [2004/2005] 2 BLSR 97
- "Innovation to Commercialization — The Role Patents Play," Canadian Chemical News, June 2005
- "Net Benefits? Internet Pharmacies in Canada," Canadian Chemical News, May 2005
- "Balancing Act," Canadian Chemical News, October 2004
- "Regulating Beauty," Canadian Chemical News, July/August 2004
- "The Patented Medicines (Notice of Compliance) Regulations" (co-author: Peter R. Wilcox), 16 Canadian Intellectual Property Reports 429, 2000
|
|
